A report by MAP BioPharma (MAP) claims that NICE’s appraisal of rare disease medicines does not deliver equal access for patients urging the company to reform. The findings show that routine availability of new medicines was “delayed or prevented entirely due to an inflexible, inappropriate assessment processes”. Of the 24 completed STA reviews of rare
NICE and EMIG are working together to increase understanding of the services the Institute offers the life sciences industry. The collaboration also aims to open up a new channel for the industry to give feedback to NICE to inform any review, monitoring or refinement of its processes. The partnership will run as a pilot scheme
Bayer’s Regorafenib has received a final approval from NICE for use by the NHS to treat advanced liver cancer. Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had Sorafenib, however they can only receive the treatment if they have Child–Pugh grade A liver impairment and an Eastern
The public body has recommended in draft guidance that UCB’s Certolizumab pegol receives regular NHS funding for plaque psoriasis, although NICE decided that Almirall’s rival Tildrakizumab is not cost effective. Certolizumab pegol has been previously approved in Europe in the new indication of plaque psoriasis, thereby adding to a list of uses including rheumatoid arthritis,
NHS has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment. NICE recommended the combination for use in patients with stage III BRAF V600 mutation-positive melanoma that has spread to lymph vessels, or lymph glands close to
A partnership between Greater Manchester and NICE that was created with the aim of improving the health of the local population has been extended for another three years. A Memorandum of Understanding has been agreed between NICE, Health Innovation Manchester and The University of Manchester outlining a shared commitment to boosting health through research, informing
Experts state that it is looking highly unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer. NICE have published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic
NICE has recommend that three separate treatments for thyroid cancer should be made available for use on the NHS: Ipsen’s Cometriq, Bayer’s Nexavar, and Eisai’s Lenvima. The former two were previously only available via the Cancer Drugs Fund (CDF), and Eisai’s finally gains approval after delays of over two years. Eisai’s tyrosine kinase inhibitor was
EUSA Pharma has gained backing from NICE for its first-line treatment for advanced renal cell carcimona (RCC), Fotivda. The recommendation from the UK’s regulatory body was decided on the result of the phase III trial TiVO-1, which evaluated the efficacy and tolerability of Fotivda compared to Bayer’s Nexavar.
NICE have issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF) in England and Wales, but only for those with moderate to severe forms of the disease. The cost regulators are sticking with its position that Esbriet should only be funded by the NHS if the person
